The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosis

Autor: Carolina Melero-Jerez, Margarita Suardíaz, Rafael Lebrón-Galán, Carmen Marín-Bañasco, Begoña Oliver-Martos, Isabel Machín-Díaz, Óscar Fernández, Fernando de Castro, Diego Clemente

Publikováno v: Neurobiology of Disease, Vol 127, Iss , Pp 13-31 (2019)

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the human central nervous system (CNS), mainly affecting young adults. Among the immunomodulatory disease modifying treatments approved up to date to treat MS, IFN-β remains to be one

Externí odkaz: https://doaj.org/article/bdc793728b8c483382a1b841c1b6bc71

Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography

Autor: Rocío Benítez-Fernández, Carolina Melero-Jerez, Carmen Gil, Enrique J. de la Rosa, Ana Martínez, Fernando de Castro

Publikováno v: International Journal of Molecular Sciences, Vol 22, Iss 5, p 2440 (2021)

The need for remyelinating drugs is essential for healing disabling diseases such as multiple sclerosis (MS). One of the reasons for the lack of this class of therapies is the impossibility to monitor remyelination in vivo, which is of utmost importa

Externí odkaz: https://doaj.org/article/2dce2a79be974eca9a0c9588fd4f35e8

Myeloid‐derived suppressor cells support remyelination in a murine model of multiple sclerosis by promoting oligodendrocyte precursor cell survival, proliferation, and differentiation

Autor: María Cristina Ortega, Ana Cristina Ojalvo, Beatriz Fernández-Gómez, Irene Sánchez-de Lara, Fernando de Castro, Diego Clemente, Rafael Lebrón-Galán, Carolina Melero-Jerez

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
Glia

The most frequent variant of multiple sclerosis (MS) is the relapsing–remitting form, characterized by symptomatic phases followed by periods of total/partial recovery. Hence, it is possible that these patients can benefit from endogenous agents th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd7a29421fefa2b013245b43fdd67f1d
https://doi.org/10.1002/glia.23936

Dynamics of central remyelination and treatment evolution in a model of Multiple Sclerosis with Optic Coherence Tomography

Autor: F. de Castro, E J de la Rosa, Carmen Gil, Ana Martínez, R. Benitez-Fernandez, Carolina Melero-Jerez

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
International Journal of Molecular Sciences, Vol 22, Iss 2440, p 2440 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 5

The need for remyelinating drugs is essential for healing disabling diseases such as multiple sclerosis (MS). One of the reasons for the lack of this class of therapies is the impossibility to monitor remyelination in vivo, which is of utmost importa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9071947c276911c48ceec74f4e83a95a
http://hdl.handle.net/10261/250359

Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis

Autor: Karim Benabdellah, Carmen Marín-Bañasco, Begoña Oliver, F. de Castro, Isaac Hurtado-Guerrero, M.J. Pinto-Medel, Diego Clemente, Laura Leyva, Margarita Suardíaz, Oscar Fernández, F Martin, Carolina Melero-Jerez

Publikováno v: British Journal of Pharmacology. 174:238-253

Background and Purpose Recombinant IFNs is one of the first line treatments in multiple sclerosis (MS), despite its lack of efficiency in some patients. In this context, mesenchymal stem cells (MSCs) represent a promising therapeutic alternative due

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a9fdecc786f0149b144ec3fd1f9c9826
https://doi.org/10.1111/bph.13674